Eli Lilly: Jardiance Improves Overall Blood Sugar Control In Children With Type 2 Diabetes

Eli Lilly and Company (LLY) said the DINAMO phase III clinical trial met its primary endpoint by showing a statistically significant reduction in HbA1c, a marker of average blood sugar, with Jardiance compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes. The overall safety data was generally consistent with previous findings in adults with type 2 diabetes. A secondary endpoint from the trial showed that at week 26, Jardiance reduced fasting plasma glucose.

The company said the findings have been submitted for publication in a peer-reviewed journal.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT